---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-24-000116"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:54:36.972664+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q2 revenue $637M, GAAP EPS $0.77; $500M buyback, FDA accepts cabozantinib sNDA

## Summary
- Total revenues $637.2M vs $469.8M YoY; cabozantinib U.S. net product revenues $437.6M.
- GAAP diluted EPS $0.77 vs $0.25 YoY; non-GAAP diluted EPS $0.84 vs $0.31.
- FDA accepted sNDA for cabozantinib in advanced NET; target action date April 3, 2025.
- Earned $150M milestone from Ipsen; completed $450M buyback; new $500M buyback authorized through 2025.
- Discontinued XB002 development; plans to initiate phase 3 for zanzalintinib in NET.

## SEC filing metadata
- accession: 0000939767-24-000116
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976724000116/0000939767-24-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976724000116/exel-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-24-000116
- JSON: https://secwatch.observer/filing/0000939767-24-000116.json
- Plain text: https://secwatch.observer/filing/0000939767-24-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.